Evaluation of galantamine and deconstructed analogs as α7 nAChR and AChE ligands

Alzheimer’s Association, 2021, Alzheimer’s disease facts and figures, Alzheimer’s Dement., 17, 327 Stelzmann, 1995, An English translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”, Clin. Anat., 8, 429, 10.1002/ca.980080612 Perry, 1995, Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology, Neuroscience, 64, 385, 10.1016/0306-4522(94)00410-7 Whitehouse, 1988, Reductions in acetylcholine and nicotine binding in several degenerative diseases, Arch. Neurol., 45, 722, 10.1001/archneur.1988.00520310028012 Davies, 1976, Selective loss of central cholinergic neurons in Alzheimer’s Disease, Lancet, 2, 1403, 10.1016/S0140-6736(76)91936-X Perry, 1977, Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue, J. Neurol. Sci., 34, 247, 10.1016/0022-510X(77)90073-9 Davis, 1999, Cholinergic markers in elderly patients with early signs of Alzheimer disease, JAMA-J. Am. Med. Assoc., 281, 1401, 10.1001/jama.281.15.1401 Bartus, 1982, The cholinergic hypothesis of geriatric memory dysfunction, Science, 217, 408, 10.1126/science.7046051 Heinrich, 2004, Galanthamine from snowdrop—the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge, J. Ethnopharmacol., 92, 147, 10.1016/j.jep.2004.02.012 Janssen, 2017, Galantamine, ChemTexts, 3, 1, 10.1007/s40828-017-0043-y Schrattenholz, 1996, Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands, Mol. Pharmacol., 49, 1 Pereira, 1994, Physostigmine and galanthamine: Probes for a novel binding site on the alpha4 beta2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells, J. Pharmacol. Exp. Ther., 270, 768 Samochocki, 2003, Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors, J. Pharmacol. Exp. Ther., 305, 1024, 10.1124/jpet.102.045773 Maelicke, 2001, Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease, Biol. Psychiatry, 49, 279, 10.1016/S0006-3223(00)01109-4 Samochocki, 2000, Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR, Acta. Neurol. Scand. Suppl., 176, 68, 10.1034/j.1600-0404.2000.00310.x Maelicke, 2000, Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer’s disease, Behav. Brain Res., 113, 199, 10.1016/S0166-4328(00)00214-X Storch, 1995, Physostigmine, galanthamine and codeine act as ‘noncompetitive nicotinic receptor agonists’ on clonal rat pheochromocytoma cells, Eur. J. Pharmacol., 290, 207, 10.1016/0922-4106(95)00080-1 Harvey, 1995, The pharmacology of galanthamine and its analogues, Pharmacol. Ther., 68, 113, 10.1016/0163-7258(95)02002-0 Fang, 2014, Design, synthesis and biological evaluation of D-ring opened galantamine analogs as multifunctional anti-Alzheimer agents, Eur. J. Med. Chem., 76, 376, 10.1016/j.ejmech.2014.02.035 Herlem, 2003, Synthesis and structure-activity relationships of open D-Ring galanthamine analogues, Med. Chem. Lett., 13, 2389, 10.1016/S0960-894X(03)00397-4 Atanasova, 2015, Galantamine derivatives with indole moiety: Docking, design, synthesis and acetylcholinesterase inhibitory activity, Bioorg. Med. Chem., 23, 5382, 10.1016/j.bmc.2015.07.058 Jia, 2009, Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors, Eur. J. Med. Chem., 44, 772, 10.1016/j.ejmech.2008.04.018 Mary, 1998, Potent acetylcholinesterase inhibitors: design, synthesis, and structure–activity relationships of bis-interacting ligands in the galanthamine series, Bioorg. Med. Chem., 6, 1835, 10.1016/S0968-0896(98)00133-3 Jordis, 2001, 12H-[2]-Benzothiepino[6,5a,5-bc]benzofuran: Synthesis of a sulfur-analog of galanthamine, Heterocycles, 55, 1727, 10.3987/COM-01-9278 Berkov, 2008, N-Alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum, Bioorg. Med. Chem. Lett., 18, 2263, 10.1016/j.bmcl.2008.03.008 Guillou, 2000, Potent acetylcholinesterase inhibitors: Design, synthesis and structure–activity relationships of alkylene linked bis-galanthamine and galanthamine–galanthaminium salts, Bioorg. Med. Chem. Lett., 10, 637, 10.1016/S0960-894X(00)00059-7 Treu, 2002, Carbocyclic galanthamine analogues: Construction of the novel 6H-benzo[a]cyclohepta[hi]benzofuran ring system, Mendeleev Commun., 12, 52, 10.1070/MC2002v012n02ABEH001557 Poschalko, 2002, Synthesis of (±)-6H-benzofuro[3a,3,2, ef][3]benzazepine: An unnatural analog of (–)-galanthamine, Tetrahedron, 58, 1513, 10.1016/S0040-4020(01)01235-2 Vezenkov, 2009, Synthesis and characterization of new galanthamine derivatives comprising peptide moiety, Protein Pept. Lett., 16, 1024, 10.2174/092986609789055412 Han, 1992, Chemical and pharmacological characterization of galanthamine, an acetylcholinesterase inhibitor, and its derivatives. A potential application in Alzheimer’s disease?, Eur. J. Med. Chem., 27, 673, 10.1016/0223-5234(92)90087-H Barniol-Xicota, 2014, Direct reductive alkylation of amine hydrochlorides with aldehyde bisulfite adducts, Tetrahedron Lett., 55, 2548, 10.1016/j.tetlet.2014.03.046 Thomsen, 1991, Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine, Eur. J. Clin. Chem. Clin. Biochem., 29, 487 Darvesh, 2003, Inhibition of human cholinesterases by drugs used to treat Alzheimer disease, Alzheimer Dis. Assoc. Disord., 17, 117, 10.1097/00002093-200304000-00011 Cer, 2009, IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding, Nucleic acids Res, 37, W441, 10.1093/nar/gkp253 Texidó, 2005, Effect of galantamine on the human α7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity, Br. J. Pharmacol., 145, 672, 10.1038/sj.bjp.0706221 Kowal, 2018, Galantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptors, Brit. J. Pharmacol., 175, 2911, 10.1111/bph.14329 Moraga-Nicolás, 2019, Galanthamine and other Amaryllidaceae related alkaloids are inhibitors of α7, α4β2 and α3β4 nicotinic acetylcholine receptors, Rev. Bras. Farmacogn., 29, 495, 10.1016/j.bjp.2019.04.003 Loesche, 2018, Unexpected AChE inhibitory activity of (2E)α, β-unsaturated fatty acids, Bioorg. Med. Chem. Lett., 28, 3315, 10.1016/j.bmcl.2018.09.013 Cheung, 2012, Structures of human acetylcholinesterase in complex with pharmacologically important ligands, J. Med. Chem., 55, 10282, 10.1021/jm300871x Glennon, 1981, Synthesis and evaluation of novel alkylpiperazines as potential dopamine antagonists, J. Med. Chem., 24, 678, 10.1021/jm00138a007 Arnold, 1955, Synthetische stoffe mit uterotonischer wirkung ii. vom 3,4-dimethoxybenzylamin abgeleitete tertiäre amine, Collect. Czech. Chem. C., 20, 567, 10.1135/cccc19550567 Stedman, 1927, The isomeric hydroxybenzyldimethylamines, J. Chem. Soc., 1902, 10.1039/JR9270001902 Jung, 1988, Improved synthesis of 3-substituted 7-methoxybenzofurans. Useful intermediates for the preparation of morphine analogs of organic chemistry, J. Org. Chem., 53, 423, 10.1021/jo00237a037 So, 2012, Concise synthesis of 2-benzazepine derivatives and their biological activity, J. Org. Chem., 77, 4017, 10.1021/jo300380z Pandit, 2009, Expedient reductive amination of aldehyde bisulfite adducts, Synthesis (Stuttg), 2009, 4032, 10.1055/s-0029-1217050 Joshi, 2004, A vertical flow chamber for Xenopus oocyte electrophysiology and automated drug screening, J. Neurosci. Methods, 132, 69, 10.1016/j.jneumeth.2003.09.002 Pecic, 2011, Nantenine as an acetylcholinesterase inhibitor: SAR, enzyme kinetics and molecular modeling investigations, J. Enzyme Inhib. Med. Chem., 26, 46, 10.3109/14756361003671078